| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae95e7759e7ecd9a4ab7f46795c1ce3 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
1998-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfe1bff43d30eabd736345b15932a953
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21a43e18de61e5d87526df377a1a6265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6eaec028b0a27edbf6c3187441936b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55330ba824d2fbb1f85dd73dd96b7ea9 |
| publicationDate |
2000-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-246999-A3 |
| titleOfInvention |
A method for reducing the administered dose of a first drug in the treatment of a disease |
| abstract |
Nucleosides selectively alter Th1 and Ih2 responses relative tonmutually treating the disease, administering the nucleosides inndrug combination limits the dose at which it is the main drugnadministered. Nucleosides increase response in the cytokine family,nselectively limit Th1 activity without significant Th2 restrictionnor selectively reduce either the h1 or Ih2 response. |
| priorityDate |
1998-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |